“New open-label data from the expanded-access treatment program involving the cannabidiol Epidiolex(GW Pharma) show the median reduction in frequency of convulsive seizures after 3 months of treatment was 45% in all patients but higher in those with Dravet syndrome, among the most severe types of epilepsy.
The data are “very positive and promising,” said lead author Orrin Devinsky, MD, professor, neurology, neurosurgery and psychiatry, and director, New York University Comprehensive Epilepsy Center.” http://www.medscape.com/viewarticle/855768
“More Positive Results With Cannabidiol in Epilepsy” http://www.medscape.com/viewarticle/853781